Overview

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

Status:
RECRUITING

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the effects of ALD-102 Solution (drug) to placebo (saline solution that contains no drug). Study participants will have two treatment areas selected on the scalp and will receive randomly ALD-102 Solution (drug) at one area and or placebo (saline solution) at the other area once every 4 weeks for a treatment period of 8 weeks.

Phase:

PHASE1

Details

Lead Sponsor:

Aldena Therapeutics

Treatments:

reproxalap